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Abstract 
There is emerging evidence of abnormal expression in human tumors of microRNAs 
(miRNAs) which have been assigned oncogenic and/or tumor suppressor functions.  
While some miRNAs commonly exhibit altered expression across tumors, more often, 
different tumor types express unique patterns of miRNAs, referable to their tissues of 
origin.  The role of miRNAs in tumorigenesis underscores their value as mechanism-
based therapeutic targets in cancer.  Similarly, unique patterns of altered microRNA 
expression provide fingerprints that may serve as molecular biomarkers for tumor 
diagnosis, classification, prognosis of disease-specific outcomes, and prediction of 
therapeutic responses. 
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Cancer is a leading cause of mortality in the United States, with ~25% of deaths 
attributable to neoplasia [1, 2].  Worldwide, cancer-related global mortality follows only 
cardiovascular and infectious diseases [3].  In this context of expanded incidence and 
growing prevalence, clinical oncology is poised for unprecedented innovation.  
Harnessing discoveries in disease pathobiology, increasingly propelled by the 
development of high-throughput technologies including genomics, proteomics and 
metabolomics, modern cancer biology offers previously unavailable diagnostic and 
therapeutic paradigms tailored to meet the needs of individuals and populations [4].  
Transforming clinical management is predicated on translation of the new science into 
application of advanced markers and targets for personalized cancer prediction, 
prevention, diagnosis, and treatment [4-6]. 
Indeed, the epigenetic, genetic, and post-genetic circuits restricting cell destiny are 
increasingly decoded, and their dysfunction linked to lineage-dependence underlying 
tumorigenesis [2, 7].  Critical in cell fate specification is post-transcriptional regulation of 
gene expression by microRNAs (Fig. 1) [8].  These molecules arise as transcripts from 
cognate genes in non-coding regions of chromosomes. MicroRNA undergo nuclear and 
cytoplasmic processing [8, 9] producing the targeting core of a multimeric complex 
hybridizing with mRNA molecules resulting in their sequestration or degradation, and 
thereby define the genes available for lineage commitment [10, 11].  This is the most 
recent addition to the hierarchical spectrum of molecular mechanisms defining nuclear-
cytoplasmic information exchange [12], and forms the interface between transcriptional, 
translational, and post-translational regulation [13]  Significantly, microRNAs represent a 
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regulatory, rather than structural, mechanism that coordinates normal gene expression 
and whose dysregulation underlies neoplastic transformation [8, 10, 11]. 
MicroRNAs and cancer 
The essential nature of this novel mechanism indelibly patterning gene expression in 
cell lineage specification [8], in the context of the established model of cancer as a 
genetic disease in which pathobiology recapitulates cell and tissue ontogeny [14, 15], 
naturally implicates microRNAs in neoplastic transformation.  In fact, altered microRNA 
expression is a defining trait of tumorigenesis [16, 17].  While the expression of some 
microRNAs are universally altered in tumors, more often unique patterns of microRNA 
expression reflect the lineage-dependence of tumors, referable to their tissues of origin 
[16-22].  Similarly, fundamental processes underlying tumorigenesis, including genomic 
instability, epigenetic dysregulation, and alterations in expression or function of 
regulatory proteins directly alter the complement of microRNAs expressed by cancer 
cells [8].  Additionally, microRNAs regulate key components integral to tumor initiation 
and progression, including tumor suppressors and oncogenes [8, 17, 23].  Further, 
microRNA signatures are a more informative source for classification of tumor taxonomy 
than genomic profiling [16].  Moreover, microRNAs can serve as unique targets for 
diagnostic imaging in vivo for taxonomic classification of tumors [24].  The emerging role 
of microRNAs in neoplasia highlights their potential value as mechanism-based 
therapeutic targets and biomarkers for diagnosis, prognosis of disease-specific 
outcomes, and prediction of therapeutic responses [25].  While there are numerous 
detailed reviews of this field, the purpose of this minireview is to provide, in overview, a 
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summary of the potential application of microRNAs as diagnostic and therapeutic 
targets in cancer. 
MicroRNAs as mechanism-based therapeutic targets in cancer 
The case for microRNAs as tumor suppressors and oncogenes reflects their loss or 
gain, respectively, as a function of neoplastic transformation, their dysregulation in 
different tumors, the relevance of their mRNA targets to mechanisms underlying 
tumorigenesis, and their ability to directly alter tumorigenesis in model cells and 
organisms (Fig. 2; Table 1) [8, 26, 27].  Typically, microRNAs that serve as oncogenes 
are characterized by a gain of expression which inhibits levels of genes encoding tumor 
suppressors.  Conversely, tumor suppressor microRNAs exhibit a loss of expression in 
cancer producing over-expression of transcripts encoded by oncogenes. 
MicroRNA Tumor Suppressors (Fig. 2, Table 1) 
The best characterized tumor suppressor microRNAs are miR-15a and miR-16-1.  B cell 
chronic lymphocytic leukemia (CLL) is the most common adult leukemia in developed 
countries and universally associated with loss of chromosomal region 13q14 [8, 27, 28].  
Within this deletion is a ~30 kb region in which resides miR-15a and miR-16-1, which 
are lost in ~70% of patients with CLL [29].  Similarly, loss of chromosomal region 13q14, 
including miR-15a and miR-16-1, occurs in prostate cancer, mantle cell lymphoma, and 
multiple myeloma [29, 30].  Tumor suppression by miR-15a and miR-16-1, in part, 
reflects inhibition of the expression of the anti-apoptotic oncogenic protein Bcl-2, which 
is characteristically over-expressed in CLL, promoting survival of leukemia cells [31].  
Indeed, there is a reciprocal relationship between expression of miR-15a and miR-16-1 
and Bcl-2, and heterologous expression of these microRNAs suppresses Bcl-2 levels 
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[32]. Suppression is specifically mediated by complimentary binding sites for those 
microRNAs in the 3’ untranslated region of the Bcl-2 transcript [32].  Further, 
heterologous expression of miR-15a and miR-16-1 produces apoptosis in leukemia cell 
lines [32].  Moreover, mouse models of spontaneous CLL possess a mutation in the 3’ 
untranslated region of miR-16-1, identical to mutations in patients with CLL, associated 
with decreased expression of that microRNA [33].  Heterologous expression of miR-16-
1 in CLL cells derived from those mice alters the cell cycle, proliferation and apoptosis 
of these tumor cells [33].  
The microRNA let-7, a phylogenetically conserved gene product that regulates the 
transition of cells from proliferation to differentiation in invertebrates [34], also serves as 
a tumor suppressor [27].  There are twelve let-7 homologs in humans forming eight 
distinct clusters of which four are localized to chromosomal regions lost in many 
malignancies [35].  In that context, downregulation of let-7 family members in lung 
cancer is associated with poor prognosis [22].  A role for these microRNAs in growth 
regulation and the expression of the tumorigenic phenotype is highlighted by the ability 
of heterologous let-7 expression in lung cancer cells in vitro to inhibit colony formation 
[36].  Key downstream targets for let-7 include the human Ras family of proteins, 
oncogenes that are commonly mutated in many human tumors [23].  Indeed, KRas and 
NRas expression in human cells is regulated by let-7 family members [27].  Moreover, 
loss of let-7 expression in human tumors correlates with over-expression of Ras 
proteins [23]. 
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MicroRNA Oncogenes (Fig. 2, Table 1) 
The miR-17 cluster comprises a group of six miRNAs (miR-17–5p, miR-18a, miR-19a, 
miR-20a, miR-19b-1 and miR-92) at 13q31–32, a chromosomal region amplified in large 
B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and primary cutaneous B-
cell lymphoma [37].  Consistent with their functions as oncogenes, over-expression of 
this microRNA cluster is associated with amplification of the 13q31–32 genomic region 
in lymphoma cells in vitro [37, 38].  These miRNAs are over-expressed in many types of 
tumors, including lymphoma, colon, lung, breast, pancreas and prostate [17, 38, 39].  
Interestingly, expression of the miR-17 cluster is induced by c-Myc, an oncogene over-
expressed in many tumors.  Heterologous expression of c-Myc up-regulates expression 
of the miR-17 cluster, mediated by direct binding of that transcription factor to the 
chromosomal region harboring those microRNAs [40].  In turn, the miR-17 cluster 
appears to regulate several downstream oncogene targets.  Thus, miR-19a and miR-
19b may regulate phosphatase and tensin homolog (PTEN), a tumor suppressor with a 
broad mechanistic role in human tumorigenesis, through interactions with 
complimentary sites in the 3’ untranslated region of this transcript [41].  Similarly, miR-
20a may reduce the expression of transforming growth factor (TGF)-β receptor II 
(TGFBR2), a tumor suppressor frequently mutated in cancer cells which regulates the 
cell cycle, imposing growth inhibition [17].  The best characterized target of the miR-17 
cluster is the E2F1 transcription factor whose expression is regulated by miR-17–5p and 
miR-20a [42].  In turn, E2F1 regulates cell cycle progression by inducing genes 
mediating DNA replication and cell cycle control [43].  Beyond the regulation of key 
targets contributing to transformation, the miR-17 cluster directly induces the 
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tumorigenic phenotype.  Heterologous expression of the miR-17 cluster increased 
proliferation in lung cancer cells in vitro [39].  Moreover, components of this cluster 
accelerate the process of lymphomagenesis in mice [44]. 
The microRNA miR-21 is over-expressed in many solid tumors including breast, colon, 
lung, prostate, stomach, and endocrine pancreas tumors, glioblastomas, and uterine 
leiomyomas [17, 45-47].  This microRNA is encoded at chromosome 17q23.2, a genetic 
locus which is frequently amplified in many tumors.  The tumorigenic effects of miR-21 
are mediated, in part, by targeting a number of mediators in critical cell survival 
pathways.  Thus, in glioblastoma cells in vitro miR-21 modulates the expression of the 
common tumor suppressor PTEN, a central regulator of cell growth, proliferation, and 
survival mediated by the PI3 kinase-Akt pathway [48].  Also, miR-21 regulates breast 
cancer cell growth by reciprocally regulating apoptosis and proliferation, in part 
reflecting regulation of the anti-apoptotic protein Bcl-2 [49].  Moreover, miR-21 controls 
expression of the tumor suppressor tropomyosin 1 whose over-expression in breast 
cancer cells suppresses anchorage-independent growth [50].  Beyond signaling 
analyses, elimination of miR-21 expression in glioblastoma cells induces caspase-
dependent apoptosis, underscoring the importance of this microRNA in mediating the 
survival phenotype [51].  Similarly, antisense oligonucleotides to miR-21 suppressed the 
growth of breast cancer cells in vitro and in xenografts in mice [48]. 
MicroRNAs as biomarkers in cancer 
Their fundamental role in development and differentiation, and their pervasive 
corruption in lineage-dependent mechanisms underlying tumorigenesis suggest that 
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microRNAs may be a particularly rich source of diagnostic, prognostic and predictive 
information as biomarkers in cancer [8, 26, 52].  Differential expression of microRNAs 
compared to their normal adjacent tissue counterparts is a characteristic of every type 
of tumor examined to date [8, 52], a feature that could be particularly useful in 
diagnosing incident cancers in otherwise normal tissues.  Indeed, this approach 
discriminates normal and neoplastic tissues in various cancer types, including CLL, 
breast cancer, glioblastoma, thyroid papillary carcinoma, hepatocellular carcinoma, lung 
cancer, colon cancer and endocrine pancreatic tumors [8, 17-22, 26, 45, 52-54].  
Similarly, microRNA expression profiles provide a powerful source of molecular 
taxonomic information, with an accuracy for classifying tumors according to their 
developmental lineage and differentiation state that surpasses mRNA expression 
profiling [16, 17].  These observations suggest the utility of microRNA expression 
profiling for identifying metastatic tumors of unknown origin, which represent ~5% of all 
malignancies worldwide [16, 17, 52].  Also, differential microRNA expression patterns 
are associated with disease prognosis [8, 52].  Specific patterns of microRNA 
expression identified patients with pancreatic cancer who survived >24 months, 
compared to those who survived <24 months [53].  In addition, the expression of 
specific microRNAs predicted overall poor survival in patients with pancreatic cancer 
[53].  Similarly, over-expression of specific microRNAs was an independent prognostic 
variable associated with advanced disease stage and decreased survival in patients 
with colon cancer [54].  Beyond diagnosis and prognosis, microRNA expression 
patterns predict responses to therapy, and over-expression of oncogenic microRNAs 
was associated with improved survival following adjuvant chemotherapy in patients with 
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colon cancer [54].  These observations highlight the potential of microRNAs as 
biomarkers for diagnosis, taxonomic classification, prognosis, risk stratification, and 
prediction of therapeutic responses in patients with cancer. 
Corruption of microRNA expression in cancer 
The genetic basis of cancer, in part, reflects chromosomal rearrangements 
encompassing translocations, deletions, amplifications, and exogenous episomal 
integrations which alter gene expression.  The essential role of microRNAs in 
tumorigenesis predicts coincidence between the location of their encoding genes and 
those cancer-associated chromosomal regions.  Indeed, more than half of microRNA 
genes are located in cancer-associated genomic regions in a wide array of tumors 
including lung, breast, ovarian, colon, gastric, liver, leukemia, and lymphoma [28, 35].  
Conversely, chromosomal regions harboring microRNAs are sites of frequent genomic 
alterations involved in cancer [28, 55].  Additionally, the impact of chromosomal 
remodeling on gene copy number directly translates to altered microRNA expression 
[19, 28, 55].  Beyond structural reorganization, epigenetic remodeling of chromosomal 
regions harboring microRNA loci contributes to transformation, and tumor-suppressing 
microRNAs silenced by CpG island hypermethylation result in dysregulation of essential 
proteins accelerating the cell cycle, including cyclin D and retinoblastoma [56, 57].  
Moreover, alterations in the machinery responsible for processing microRNA contributes 
to tumorigenesis, and impairment of Dicer enhances lung tumor development in 
experimental mouse models and is associated with poor prognosis in patients with lung 
cancer [58-60]. 
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Therapeutic targeting of microRNAs 
The causal role of microRNAs in molecular mechanisms underlying transformation and 
the contribution of specific microRNA species to lineage-dependent tumorigenesis 
suggest that these molecules could serve as therapeutic targets to prevent and treat 
cancer [61].  In the context of established therapeutic paradigms in medical oncology, 
individualized therapy with microRNAs could re-establish the expression of silenced 
microRNA tumor suppressors, while antisense oligonucleotides could silence over-
expressed oncogenic microRNAs [8, 28, 52, 61].  Indeed, antisense oligonucleotides 
targeted to microRNA sequences (AMOs) with modified RNA backbone chemistry 
resistant to nuclease degradation irreversibly eliminates over-expression of oncogenic 
microRNAs [61].  Similarly, locked nucleic acid analogs resist degradation and stabilize 
the microRNA target-antisense duplex required for silencing [62].  Moreover, single 
stranded RNA molecules complimentary to oncogenic microRNAs, termed antagomirs, 
silence microRNA expression in mouse models in vivo [63].  The specificity of targeting 
inherent in nucleic acid base complimentarity coupled with their mechanistic role in 
neoplastic transformation make microRNAs attractive therapeutic targets for future 
translation. 
Summary 
MicroRNAs represent one fundamental element of the integrated regulation of gene 
expression underlying nuclear-cytoplasmic communication.  Disruption of these 
regulatory components in processes underlying tumor initiation and promotion 
contributes to the genetic basis of neoplasia.  Beyond molecular mechanisms 
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underlying pathophysiology that constitute therapeutic targets, unique patterns of 
microRNA expression characterizing lineage dependent tumorigenesis offer unique 
opportunities to develop biomarkers for diagnostic, prognostic, and predictive 
management of cancer.  These novel discoveries are positioned to launch a 
transformative continuum linking innovation to patient management.  Advancement of 
these novel paradigm-shifting concepts into patient application will proceed through 
development and regulatory approval to establish the evidence basis for integration of 
microRNA-based diagnostics and therapeutics into clinical practice.   
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Table 1.  MicroRNAs in tumorigenesis 
 
MicroRNA 
Gene 
Locus 
Tumor 
Types 
Gene 
Targets 
 
Ref 
Suppressors     
mir-15a, 16-1 13q14 CLL, prostate, mantle cell 
lymphoma, multiple 
myeloma 
BCL-2 28-32 
let-7 8 clusters lung, gastric RAS 22, 23, 26, 
34, 35 
Oncogenes     
mir-17 cluster 13q31-32 B-CLL, follicular 
lymphoma, mantle cell 
lymphoma, cutaneous B 
cell lymphoma, colon, 
lung, breast, pancreas, 
prostate 
PTEN 
TGFβ RII 
E2F1 
17, 36-38, 
40-43 
mir-21 17q23.2 breast, colon, lung, 
prostate, gastric, 
endocrine pancreas, 
glioblastomas, 
leiomyomas 
PTEN 
BCL-2 
Tropomyosin I 
17, 44-50, 
54 
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FIGURE LEGENDS 
Figure 1.  MicroRNA generation and gene regulation [9].  Mature microRNAs of 
about 22 nucleotides originate from primary microRNA (pri-microRNA) transcripts.  
Nuclear pri-microRNAs of hundreds to thousands of base pairs are converted into stem-
loop precursors (pre-microRNA) of about 70 nucleotides by Drosha, an RNase III 
endonuclease, and Pasha, a homologue of the human DiGeorge syndrome critical 
region gene 8 (DGCR8).  Pre-microRNAs undergo cytoplasmic translocation mediated 
by exportin 5 in conjunction with Ran-GTP and subsequently processed into RNA 
duplexes of about 22 nucleotides by Dicer, an RNase III enzyme, and Loqacious (Loqs), 
a double-stranded RNA-binding–domain protein that is a homologue of the HIV 
transactivating response RNA-binding protein (TRBP).  The functional strand of the 
microRNA duplex guides the RNA-induced silencing complex (RISC) to the mRNA 
target for translational repression or degradation. 
Figure 2.  MicroRNA oncogenes and tumor suppressors [26].  a. Normally, 
microRNA (miRNA) binding to target mRNA represses gene expression by blocking 
protein translation or inducing mRNA degradation, contributing to homeostasis of 
growth, proliferation, differentiation and apoptosis.  b. Reduced miRNA levels, reflecting 
defects at any stage of mirRNA biogenesis (indicated by question marks), produce 
inappropriate expression of target oncoproteins (purple squares).  The resulting defects 
in homeostasis increase proliferation, invasiveness or angiogenesis or decrease levels 
of apoptosis or differentiation, potentiating tumor formation.  c. Conversely, 
overexpression of an oncogenic miRNA eliminates the expression of tumor-suppressor 
genes (pink), leading to cancer progression.  Increased levels of mature miRNA could 
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reflect amplification of the miRNA gene, a constitutively active promoter, increased 
efficiency in miRNA processing or increased stability of the miRNA (indicated by 
question marks). ORF, open reading frame.  
 
